Yue R. · Liu X.

Author affiliations

Division of Hepatology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: September 23, 2022
Accepted: December 04, 2022
Published online: February 06, 2023

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

Introduction: Liver surgery leads to a high degree of heterogeneity in the prognosis of hepatocellular carcinoma (HCC) patients. However, most previous studies focused on the postoperative therapeutic effects of other treatments, with relatively few studies on the impacts on liver function. This study investigated the impact of transarterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC) on liver function after HCC resection from various angles. Methods: 138 HCC patients were enrolled, including 27 patients who received TACE and 80 patients who received HAIC. Besides routine treatment such as liver protection and antiviral therapy, 31 patients received no other treatment. The different groups were compared with various biological parameters with four types of scoring methods. Results: In the short term after TACE, the mean (±SD) alanine transaminase and aspartate transaminase values increased by 79.22 ± 117.43 U/L and 66.33 ± 94.54 U/L, respectively (p < 0.01). The mean (±SD) total bilirubin (TBIL) values increased by 4.02 ± 6.08 μmol/L (p < 0.01). The mean (±SD) albumin (ALB) values decreased by 3.54 ± 2.93 g/L (p < 0.001). The mean (±SD) albumin bilirubin (ALBI) scores increased by 0.39 ± 0.22 (p < 0.001). In the short term after HAIC, the mean (±SD) TBIL values increased by 2.11 ± 5.57 μmol/L (p < 0.01). The mean (±SD) ALB values decreased by 2.52 ± 3.26 g/L (p < 0.001), and the mean (±SD) ALBI scores increased by 0.21 ± 0.42 (p < 0.001). In both treatment groups, the long-term liver function was not significantly different from that before treatment and also from that of the untreated group (p > 0.05). Conclusion: TACE after HCC resection has a significant impact on short-term liver function, whereas HAIC has a relatively small impact, but neither has a major impact on long-term liver function.

© 2023 S. Karger AG, Basel

References Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the international study group of liver surgery (ISGLS). Surgery. 2011 May;149(5):713–24. Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2.2021, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541–65. Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (meld). Hepatology. 2007 Mar;45(3):797–805. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the albi grade. J Clin Oncol. 2015 Feb 20;33(6):550–8. Tomassini F, Giglio MC, De Simone G, Montalti R, Troisi RI. Hepatic function assessment to predict post-hepatectomy liver failure: what can we trust? a systematic review. Updates Surg. 2020 Dec;72(4):925–38. Asenbaum U, Kaczirek K, Ba-Ssalamah A, Ringl H, Schwarz C, Waneck F, et al. Post-hepatectomy liver failure after major hepatic surgery: not only size matters. Eur Radiol. 2018 Nov;28(11):4748–56. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar 31;391(10127):1301–14. Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a european perspective. Liver Cancer. 2014 May;3(2):119–24. Ocak İ, Topaloğlu S, Acarli K. Posthepatectomy liver failure. Turk J Med Sci. 2020 Oct 22;50(6):1491–503. Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L, et al. Adjuvant transarterial chemoembolization for hbv-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018 May 1;24(9):2074–81. Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun. 2018 Oct 10;38(1):61. Liu C, Sun L, Xu J, Zhao Y. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. World J Surg Onc. 2016 Apr 2;14(1):100. Li KW, Li X, Wen TF, Lu WS. The effect of postoperative tace on prognosis of hcc: an update. Hepatogastroenterology. 2013 Mar-Apr;60(122):248–51. Ke-Wei L, Tian-Fu W, Xi L, Lü-Nan Y, Bo L, Yong Z, et al. The effect of postoperative tace on prognosis of hcc with microscopic venous invasion. Hepatogastroenterology. 2012;59(118):1944–6. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010 Jul;78(Suppl 1):148–53. Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. Sorafenib for advanced hepatocellular carcinoma. J Hepatol.2018 Jul;69(1):60–9. Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015 Apr 7;21(13):3843–9. Bouchahda M, Lévi F, Adam R, Rougier P. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur J Cancer. 2011 Dec;47(18):2681–90. Nitta H, Beppu T, Imai K, Hayashi H, Chikamoto A, Baba H. Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. World J Surg. 2013 May;37(5):1034–42. Tanaka S, Shimada M, Shirabe K, Maehara SI, Harimoto N, Tsujita E, et al. A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma. Hepatogastroenterology. 2005 May-Jun;52(63):862–5. Asahara T, Itamoto T, Katayama K, Ono E, Dohi K, Nakanishi T, et al. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma: results of long-term follow-up. Hepatogastroenterology. 1999 Mar-Apr;46(26):1042–8. Takagi K, Koyama T, Hasegawa M, Manabe K. [The effect of hepatic arterial infusion chemotherapy on the prognosis after hepatectomy for hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1998 Mar;25(4):597–600. Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y, et al. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer. 2007 Dec 1;110(11):2493–501. Fukuda S, Okuda K, Imamura M, Imamura I, Eriguchi N, Aoyagi S. Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery. 2002;131(3):300–10. Huang YH, Wu JC, Lui WY, Chau GY, Tsay SH, Chiang JH, et al. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg. 2000 May;24(5):551–5. Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and ast/alt in primary hepatic carcinoma. Bmc Cancer. 2019 Aug 27;19(1):841. Costa AF, Tremblay St-Germain A, Abdolell M, Smoot RL, Cleary S, Jhaveri KS. Can contrast-enhanced mri with gadoxetic acid predict liver failure and other complications after major hepatic resection? Clin Radiol. 2017 Jul;72(7):598–605. Yoon JH, Choi JI, Jeong YY, Schenk A, Chen L, Laue H, et al. Pre-treatment estimation of future remnant liver function using gadoxetic acid mri in patients with hcc. J Hepatol. 2016 Dec;65(6):1155–62. Cho SH, Kang UR, Kim JD, Han YS, Choi DL. The value of gadoxetate disodium-enhanced mr imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study. Eur J Radiol. 2011 Nov;80(2):e195–200. Wibmer A, Prusa AM, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A. Liver failure after major liver resection: risk assessment by using preoperative gadoxetic acid-enhanced 3-t mr imaging. Radiology. 2013 Dec;269(3):777–86. Ishikawa T, Kubota T, Horigome R, Kimura N, Honda H, Iwanaga A, et al. Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve. Hepatol Res. 2014;44(11):1056–61. Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, et al. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2012 Mar 28;18(12):1379–84. Lu W, Li YH, Yu ZJ, He XF, Chen Y, Zhao JB, et al. A comparative study of damage to liver function after tace with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology. 2007 Jul-Aug;54(77):1499–502. Zhao S, Wang M, Yang Z, Tan K, Zheng D, Du X, et al. Comparison between child-pugh score and albumin-bilirubin grade in the prognosis of patients with hcc after liver resection using time-dependent roc. Ann Transl Med. 2020 Apr;8(8):539. Wang YY, Zhong JH, Su ZY, Huang JF, Lu SD, Xiang BD, et al. Albumin-bilirubin versus child-pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016 May;103(6):725–34. Article / Publication Details

First-Page Preview

Received: September 23, 2022
Accepted: December 04, 2022
Published online: February 06, 2023

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.